NCT02321748View on ClinicalTrials.gov

Drug-Drug Interaction Study: ASP2151 and Montelukast

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Healthy
Interventions
DRUG

Montelukast

DRUG

ASP2151

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research Ltd, London

All Listed Sponsors
lead

Maruho Europe Limited

INDUSTRY

NCT02321748 - Drug-Drug Interaction Study: ASP2151 and Montelukast | Biotech Hunter | Biotech Hunter